Sarcoidosis is a multisystem disease which may present with non-specific symptoms or symptoms related to organ-specific involvement.
Non-specific symptoms include fever, malaise, fatigue and weight loss.
Pulmonary involvement is seen in >90% of sarcoidosis patients.
  1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ER. Am J Respir Crit Care Med. 1999 Aug;160(2):736-755. PMID: 10430755
  2. Baltzan M, Mehta S, Kirkham TH, et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999 Jul;160(1):192-197. PMID: 10390399
  3. Baughman RP. Pulmonary sarcoidosis. Clin Chest Med. 2004 Sep;25(3):521-530, vi. PMID: 15331189
  4. Baculard A, Blanc N, Boulé M, et al. Pulmonary sarcoidosis in children: a follow-up study. Eur Respir J. 2001 Apr;17(4):628-635. PMID: 11401056
  5. Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax. 1999 Aug;54(8):742-746. PMID: 10413729
  6. British Thoracic Society. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction. Thorax. 1999 Apr;54(Suppl 1):S1-S14. PMID: 11006787
  7. Costabel U. Sarcoidosis: clinical update. Eur Respir J Suppl. 2001 Sep;18(32):56s-68s. PMID: 11816825
  8. du Bois RM, Greenhalgh PM, Southcott AM, et al. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J. 1999 Jun;13(6):1345-1350. PMID: 10445610
  9. Gibson GJ. Sarcoidosis: old and new treatments. Thorax. 2001 May;56(5):336-339. PMID: 11312398
  10. Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore). 1999 Mar;78(2):65-111. PMID: 10195091
  11. Milman N. Oral and inhaled corticosteroids in the treatment of pulmonary sarcoidosis-a critical reappraisal. Sarcoidosis Vasc Diffuse Lung Dis. 1998 Sep;15(2):150-157. PMID: 9789893
  12. Morey SS. American Thoracic Society issues consensus statement on sarcoidosis. Am Fam Physician. 2000 Jan;61(2):553-556. PMID: 10670511
  13. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest. 1999 Apr;115(4):1158-1165. PMID: 10208222
  14. Paramothayan NS, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA. 2002 Mar;287(10):1301-1307. PMID: 11886322
  15. Paramothayan NS, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2000(4):CD001114. PMID: 11034698
  16. Pacheco Y, Marechal C, Marechal F, et al. Azathioprine treatment of chronic pulmonary sarcoidosis. Sarcoidosis. 1985 Sep;2(2):107-113. PMID: 3031790
  17. Pietinalho A, Tukiainen P, Haahtela T, et al. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group. Chest. 1999 Aug;116(2):424-431. PMID: 10453872
  18. Pietinalho A, Tukiainen P, Haahtela T, et al. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest. 2002 Jan;121(1):24-31. PMID: 11796428
  19. Paramothayan S, Lasserson T, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2003(3):CD003536. PMID: 12917971
  20. Wu JJ, Schiff KR. Sarcoidosis. Am Fam Physician. 2004 Jul;70(2):312-322. PMID: 15291090
  21. Sharma OP. Pulmonary sarcoidosis: management. J Postgrad Med. 2002 Apr;48(2):135-141. PMID: 12215701
  22. MedWorm
  23. Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med. 2013 Sep;19(5):545-561. PMID: 23880702
  24. Drent M, Cremers JP, Jansen TL, Baughman RP. Practical eminence and experience-based recommendations for use of TNF-aplha inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):91-107. Accessed 6 Aug 2014. PMID: 25078637
  25. Jara-Palomares L, Caballero-Eraso C, Diaz-Baquero A, Rodriguez-Portal JA. Updated guidelines for the treatment of pulmonary sarcoidosis. Sarcoidosis diagnosis and management. Croatia: InTech; 2011. Accessed 6 Aug 2014.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 21 Nov 2018
Use of triple therapy consisting of a long acting muscarinic antagonist (LAMA), long acting β agonist (LABA) and inhaled corticosteroid (ICS) leads to a reduced rate of moderate or severe exacerbations of chronic obstructive pulmonary disease (COPD) and better lung function and health-related quality of life compared with dual therapy (ICS and LABA or LAMA and LABA) or LAMA monotherapy, according to the results of a meta-analysis.